SIRPA and nasopharyngeal carcinoma: Thanks to its promising preclinical results, many clinical trials have been initiated in recent years to study various therapeutic variants such as anti-CD47 antibodies (Hu5F9-G4 and CC-90002), engineered high-affinity SIRP (ALX148) and SIRP-Fc fusion (TTI-621) [65, 66] We found that SCARB1 in NPC-derived EVs can inhibit macrophage phagocytosis and promote NPC metastasis by upregulating CYP1B1 in M2 macrophages, so targeting SCARB1 is likely to be a new target for NPC metastasis treatment.